Syntheses and Spectral Characterization of the Metabolites of a New Organo‐Selenium Drug: Ebselen
- 1 January 1987
- journal article
- research article
- Published by Wiley in Bulletin des Sociétés Chimiques Belges
- Vol. 96 (5) , 383-389
- https://doi.org/10.1002/bscb.19870960506
Abstract
The syntheses and spectral characterization of the metabolites of a new organo‐selenium drug (ebselen) are described.Keywords
This publication has 13 references indexed in Scilit:
- A novel biologically active seleno-organic compound—VIBiochemical Pharmacology, 1986
- Ebselen reduces the formation of LTB4 in human and porcine leukocytes by isomerisation to its 5S, 12R-6-trans-isomerProstaglandins, 1986
- An experimental model for hydrogen peroxide–induced tissue damage. Effects of a single inflammatory mediator on (peri)articular tissuesArthritis & Rheumatism, 1986
- Selective inhibition of leukotriene B4 formation by Ebselen: A novel approach to antiinflammatory therapyInflammation Research, 1986
- Synthesis of 75Se‐2‐phenyl‐1,2‐benzisoselenazol‐3(2H)‐one (PZ 51; ebselen. A novel biologically active organo‐selenium compoundJournal of Labelled Compounds and Radiopharmaceuticals, 1986
- Ebselen and other lipoxygenase inhibitors: Comparative inhibition of arachidonate oxygenation and cobra venom factor oedemaInternational Journal of Immunopharmacology, 1985
- A novel biologically active seleno-organic compound—IIIBiochemical Pharmacology, 1984
- A novel biologically active seleno-organic compound—IIBiochemical Pharmacology, 1984
- A novel biologically active seleno-organic compound—1Biochemical Pharmacology, 1984
- EbselenDrugs of the Future, 1984